Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/cjn.2021.219 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unlabelled: Mild hypoxic-ischemic encephalopathy is common in neonates with no evidence-based therapies, and 30-40% of patients experience adverse outcomes. The nature and progression of mild injury is poorly understood. Thus, we studied the evolution of mild perinatal brain injury using longitudinal two-photon imaging of transgenic fluorescent proteins as a novel readout of neuronal viability and activity at cellular resolution.
View Article and Find Full Text PDFNitrile-aminothiol bioorthogonal near-infrared fluorogenic probes for ultrasensitive in vivo imaging.
Nat Commun
January 2025
State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
Bioorthogonal chemistry-mediated self-assembly holds great promise for dynamic molecular imaging in living organisms. However, existing approaches are limited to nanoaggregates with 'always-on' signals, suffering from high signal-to-background ratio (SBR) and compromised detection sensitivity. Herein we report a nitrile-aminothiol (NAT) bioorthogonal fluorogenic probe (CyNA-SS-FK) for ultrasensitive diagnosis of orthotopic hepatocellular carcinoma.
View Article and Find Full Text PDFA novel injectable nanotherapeutic platform increasing the bioavailability and anti-tumor efficacy of Arachidonylcyclopropylamide on an ectopic non-small cell lung cancer xenograft model: A randomized controlled trial.
Int J Pharm
December 2024
Hacettepe University, Faculty of Medicine, Department of Histology and Embryology, 06100, Sıhhiye, Ankara, Turkey; METU MEMS Center, 06530, Ankara, Turkey. Electronic address:
Rapid progressing non-small cell lung adenocarcinoma (NSCLC) decreases treatment success. Cannabinoids emerge as drug candidates for NSCLC due to their anti-tumoral capabilities. We previously reported the controlled release of Arachidonylcyclopropylamide (ACPA) selectively targeting cannabinoid 1 (CB1) receptor in NSCLC cells in vitro.
View Article and Find Full Text PDFTenecteplase Thrombolysis for Stroke up to 24 Hours After Onset With Perfusion Imaging Selection: The CHABLIS-T II Randomized Clinical Trial.
Stroke
January 2025
Department of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China (X.C., L.H., Y.L., Yiran Zhang, X.L., S.L., L.Y., Q.D.).
Background: Whether it is effective and safe to extend the time window of intravenous thrombolysis up to 24 hours after the last known well is unknown. We aimed to determine the efficacy and safety of tenecteplase in Chinese patients with acute ischemic stroke due to large/medium vessel occlusion within an extended time window.
Methods: Patients with ischemic stroke presenting 4.
Long-term clinical study of fixed prosthetic rehabilitation using one-piece narrow-diameter implants: a retrospective study.
J Korean Assoc Oral Maxillofac Surg
December 2024
Department of Prosthodontics, Section of Dentistry, Seoul National University Bundang Hospital, Seongnam, Korea.
Article Synopsis
- The study aimed to assess the long-term outcomes of one-piece narrow-diameter implants (NDIs) and identify factors influencing marginal bone loss (MBL) around them.
- The analysis involved 25 patients and 40 NDIs over an average of 10.5 years, with a high survival rate of 95.1% for implants and a mean MBL of 0.44 mm, primarily linked to the use of guided bone regeneration (GBR).
- The findings suggest that NDIs perform well clinically over time, showing acceptable MBL, but further research with larger samples is recommended to confirm these results.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!